Project Summary: B cells have a critical role in multiple sclerosis as seen by clinical trials. Their maintenance is largely regulated by the BAFF-APRIL system. B cells affect inflammatory diseases via their immune-regulatory capacity and via antibody production. Some MS patients have antibodies to myelin oligodendrocyte glycoprotein (MOG). Goal of this project is to characterize B-cell regulatory and effector mechanisms in MS. Therefore we
a) Analyze membrane bound and shed isoforms of the BAFF+APRIL receptor TACI in vivo and in vitro;
b) Determine regulation of IL-35 production by B cells;
c) Examine functional features of antibodies to MOG using affinity purified and human recombinant antibodies in myelinating cultures and animal models.

Principal Investigators:

Prof. Dr. med. Reinhard Hohlfeld,
Institut für Klinische Neuroimmunologie
Biomedizinisches Zentrum & Klinikum Großhadern
Ludwig-Maximilians-Universität München
Marchioninistr. 15
81377 München
Tel.: +49 89 4400 74781
E-Mail: reinhard.hohlfeld@med.uni-muenchen.de,

Prof. Dr. med. Edgar Meinl
Institut für Klinische Neuroimmunologie
Biomedizinisches Zentrum
Ludwig-Maximilians-Universität München
Großhaderner Str. 9
82152 Planegg-Martinsried
Tel.: +49 89 2180 71665
E-Mail: edgar.meinl@med.uni-muenchen.de